BPC-157 for nerve damage has only been studied in animals. Rat studies report better sciatic nerve and spinal cord healing, but no human nerve trial exists. Compounded BPC-157 is not FDA-approved, and any use is a TelosRX provider decision.
Nerve injuries heal slowly, and the options can feel thin. So it's no surprise BPC-157 for nerve damage is a popular search.
This review walks through what the published studies actually found. Each finding is cited. Each one is framed as evidence, not a promise.
Short version: the animal signals are interesting and fairly consistent. The human evidence for nerves is zero.
What Is BPC-157?
BPC-157 is a synthetic peptide (a short chain of amino acids). It's a 15-amino-acid fragment based on a protein found in gastric juice. "BPC" stands for Body Protection Compound.
Most of the research comes from one group at the University of Zagreb. They've published on it for about three decades, mostly in rats. For the basics, see how BPC-157 works.
- Not FDA-approved for any condition
- No published human trial for nerve injury or neuropathy
- Prohibited in sport by the World Anti-Doping Agency
- Available in the US only as a compounded or research product
How Nerve Damage Heals, in Brief
Peripheral nerves (outside the brain and spine) can regrow, but slowly. Recovery is often measured in months. Long gaps and older injuries recover less completely.
The spinal cord and brain are tougher. Damage there tends to trigger a second wave of injury from swelling, bleeding and inflammation. Researchers call this "secondary injury."
That's the backdrop for the BPC-157 studies below. Most test whether the peptide changes healing after a deliberate injury in rats.
The Evidence at a Glance
| Study | Model | What it reported | What it can't tell you |
|---|---|---|---|
| Gjurasin et al., 2010 | Cut sciatic nerve, rats | Faster axon regrowth, better nerve signals and walking scores | Any effect in human nerve injury |
| Perović et al., 2019 | Spinal cord compression, rats | Tail function recovery; less axon and neuron loss over one year | Human dosing or safety |
| Perović et al., 2022 | Spinal cord injury, rats, delayed start | Recovery even when started 4 days after injury, including oral dosing | Whether delayed use helps people |
| Tudor et al., 2010 | Traumatic brain injury, mice | Less bleeding, swelling and early deaths | Long-term brain outcomes |
| Vukojević et al., 2020 | Brain blood-flow injury, rats | Less neuron damage; better memory and balance tests | Stroke recovery in people |
| Poolton et al., 2026 | Systematic review, humans | Only 3 small human studies (30 people), none on nerves | Any human nerve efficacy |
Finding 1: Sciatic Nerve Repair in Rats
The key peripheral nerve study is Gjurasin et al. in Regulatory Peptides (2010). Researchers cut the sciatic nerve in rats and gave BPC-157 shortly afterward.
They tried several routes: injected into the abdomen, given by mouth, and applied right at the repair site. They also tested a version where a nerve gap was bridged with a tube.
The authors reported that treated rats showed:
- Faster axon regrowth (axons are the long "wires" of nerve cells)
- More and thicker myelinated fibers (myelin is the nerve's insulation)
- Stronger muscle signals on EMG testing
- Better walking scores on the sciatic functional index
- No self-biting of the numb paw, a common sign of nerve injury in rats
The limit: one rat study, from the lab that developed the peptide. It hasn't been repeated in humans.
Finding 2: Spinal Cord Compression in Rats
A 2019 study in the Journal of Orthopaedic Surgery and Research tested BPC-157 after spinal cord compression. The injury caused tail paralysis in rats.
A single injection was given 10 minutes after injury. The rats were followed for up to a year.
The authors reported:
- Steady recovery of tail movement in treated rats
- Spasticity resolved by day 15
- Less loss of axons and motor neurons under the microscope
- Less demyelination (loss of nerve insulation) and cyst formation
Untreated rats kept their paralysis. The authors suggested BPC-157 may act on the secondary injury phase.
Finding 3: Benefit Even With a Delayed Start
Most injury studies start a test compound within minutes. Real life rarely works that way. So a 2022 follow-up in Current Issues in Molecular Biology asked a sharper question.
The same group started BPC-157 four days after spinal cord injury, once paralysis was established. One arm gave it orally in drinking water for a month.
They reported faster tail recovery and no demyelination in treated rats. It's an intriguing result. It also comes from the same lab, in rats, with a narrow injury model.
Finding 4: Brain Injury in Mice
Nerve damage isn't only peripheral. Tudor et al. (2010) tested BPC-157 in mice after a weight-drop head injury, a standard concussion model.
The researchers reported less brain bleeding, less swelling and fewer early deaths in the first 24 hours. That's a short window. It says nothing about recovery weeks or months later.
For the broader brain picture, see our review of BPC-157 for brain health.
Finding 5: Blood-Flow Injury to the Brain
Vukojević et al. (2020) clamped both carotid arteries in rats for 20 minutes, then restored blood flow. This mimics the damage of a stroke-like event.
Rats given BPC-157 during reflow had less early and delayed neuron damage. They also did better on maze, beam-walking and balance tests. Gene changes pointed toward blood-vessel and nitric oxide pathways.
Finding 6: What the Reviews Conclude
A 2022 review in Neural Regeneration Research pulled this work together. It's titled "Pentadecapeptide BPC 157 and the central nervous system".
The review describes effects across nerve, spinal cord, brain injury and toxin models in rodents. Most authors are from the original Zagreb group. Independent replication remains limited.
Finding 7: Human Evidence Is Close to Zero
This is the most important finding. A 2026 PRISMA-registered systematic review by Poolton and colleagues searched every major database through June 2026.
- Only 3 human studies met criteria, with 30 people total
- Knee pain injections (16), bladder instillations (12) and an IV safety pilot (2)
- No nerve, neuropathy or spinal cord studies
- All rated poor quality, with very low certainty of evidence
The authors concluded BPC-157 should not be used clinically outside regulated, high-quality trials. That's a sober message. It's worth hearing.
Why Rat Nerve Results May Not Translate
Rats regrow nerves faster than people. Their nerves are also much shorter, so distances are tiny. A result that looks dramatic in a rat paw may shrink in a human leg.
- Clean injuries. Lab nerve cuts are precise. Human injuries are messy and varied.
- Fast timing. Most studies dosed within minutes of injury.
- One main lab. Few independent groups have tested the same models.
- Different conditions. Diabetic neuropathy, for example, has not been studied with BPC-157 in people.
Safety and Regulatory Status
Animal studies from the main group report few toxic effects. Human safety data, though, is tiny. Long-term human safety is unknown.
Product quality is a real concern in the unregulated "research use only" market. Wrong doses and contaminants are both possible. That's one reason licensed prescribing and pharmacy sourcing matter.
Athletes should know BPC-157 is on the WADA prohibited list. Curious how long it lingers? See how long BPC-157 stays in your system.
Where BPC-157 Fits at TelosRX
TelosRX offers compounded BPC-157 for adults when a licensed provider decides it's appropriate. It is not FDA-approved, and we don't present it as a nerve therapy.
Nerve symptoms deserve a proper workup first. Numbness, weakness or burning pain can have causes that need specific care.
Considering peptides as part of a recovery plan? Learn about BPC-157 injection at TelosRX. Any prescription is subject to medical approval by a licensed provider through an asynchronous online review. Approval is not guaranteed.
Questions to Ask Before Considering BPC-157
- Has a clinician confirmed the cause of my nerve symptoms?
- Have I tried evidence-based options for my specific condition?
- Is the product from a licensed, regulated pharmacy?
- What are the known and unknown risks for my health history?
- How will we judge whether anything is actually changing?
Frequently Asked Questions
Does BPC-157 help with nerve damage?
Rat studies report faster sciatic nerve regrowth and better spinal cord recovery with BPC-157. But no human trial has tested it for nerve damage or neuropathy. Animal results often fail to carry over to people. Compounded BPC-157 is not FDA-approved, and any use should be a licensed provider's decision based on your history.
Is there human research on BPC-157 for neuropathy?
No. A 2026 systematic review found only three small human studies of BPC-157, with 30 people in total. They looked at knee pain, bladder symptoms and IV safety. None examined peripheral neuropathy, nerve injury or spinal cord injury, and all were judged to be of poor methodological quality.
What is BPC-157 used for in research?
Researchers have studied BPC-157 mainly in rat models of gut injury, tendon and ligament healing, muscle injury, and nerve, spinal cord and brain injury. Nearly all of this work is preclinical and comes from one research group. It is not FDA-approved for any use, and research interest does not establish clinical benefit in people.
Is oral or injected BPC-157 studied for nerves?
Both routes appear in rat nerve studies. The 2010 sciatic nerve study used injected, oral and local application. A 2022 spinal cord study gave BPC-157 in drinking water starting four days after injury. No human study has compared oral and injected BPC-157 for any nerve condition.
Is BPC-157 safe?
Animal studies from the main research group report few toxic effects, but human safety data is very limited and long-term safety is unknown. Products sold as research chemicals may have quality problems. A licensed provider can review your history, and a regulated pharmacy reduces sourcing risk, though neither removes the evidence gaps.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for nerve damage or any other condition. In the US it is available only as a compounded medication prepared under federal compounding regulations or as an unregulated research product. Compounded versions have not been through FDA review for safety and effectiveness.
The Bottom Line on BPC-157 for Nerve Damage
- Rat studies show consistent nerve and spinal cord healing signals.
- Most come from one lab and use tidy, early-dosed injury models.
- There are no human nerve trials, and overall human data is tiny.
- Get nerve symptoms properly assessed first.
Interesting science? Yes. Proven nerve therapy? Not yet.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.